Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Messing

Showing results (51-60 of 199) with videos related to

Pageof 20
Sort By:
Urologic Oncology|April 15, 2004
Gender, racial and age differences in bladder cancer incidence and mortalityRalph Madeb, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|March 5, 2026
Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancerKamil Malshy, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|May 13, 2026
A risk-adapted approach to reTURBT in high-grade T1 NMIBCKamil Malshy, Edward M Messing
Urology Practice|November 2, 2023
Editorial CommentTrevor C Hunt, Edward M Messing
The Urologic Clinics of North America|July 12, 2002
Timing hormonal therapy in prostate cancerAnnette E Sessions, Edward M Messing
Nature Clinical Practice. Urology|May 13, 2006
Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?Ganesh S Palapattu, Edward M Messing
Urology|September 29, 2015
Editorial CommentJanet Baack Kukreja, Edward M Messing
European Urology|May 3, 2025
Re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. 2025;87:444-452Kamil Malshy, Jathin Bandari, Edward M Messing
The Prostate|September 25, 2004
Androgen deprivation therapy for prostate cancer: current status and future prospectsHiroshi Miyamoto, Edward M Messing, Chawnshang Chang
Nature Clinical Practice. Oncology|November 3, 2005
Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?Hiroshi Miyamoto, Edward M Messing, Chawnshang Chang
Pageof 20

Showing results (51-60 of 199) with videos related to

Sort By:
Pageof 20
Urologic Oncology|April 15, 2004
Gender, racial and age differences in bladder cancer incidence and mortalityRalph Madeb, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|March 5, 2026
Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancerKamil Malshy, Edward M Messing
Bladder Cancer (Amsterdam, Netherlands)|May 13, 2026
A risk-adapted approach to reTURBT in high-grade T1 NMIBCKamil Malshy, Edward M Messing
Urology Practice|November 2, 2023
Editorial CommentTrevor C Hunt, Edward M Messing
The Urologic Clinics of North America|July 12, 2002
Timing hormonal therapy in prostate cancerAnnette E Sessions, Edward M Messing
Nature Clinical Practice. Urology|May 13, 2006
Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?Ganesh S Palapattu, Edward M Messing
Urology|September 29, 2015
Editorial CommentJanet Baack Kukreja, Edward M Messing
European Urology|May 3, 2025
Re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. 2025;87:444-452Kamil Malshy, Jathin Bandari, Edward M Messing
The Prostate|September 25, 2004
Androgen deprivation therapy for prostate cancer: current status and future prospectsHiroshi Miyamoto, Edward M Messing, Chawnshang Chang
Nature Clinical Practice. Oncology|November 3, 2005
Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?Hiroshi Miyamoto, Edward M Messing, Chawnshang Chang
Pageof 20